Sunday, November 22, 2026
Toba Tek Singh

New weight-loss drugs cut teen BMI by up to 18.5 per cent

November 22, 2026
0

4min read

Key Points:

  • Childhood obesity is a major risk to a child’s future health, not just extra weight.
  • Timely weight control cuts the risk of type 2 diabetes and heart disease.
  • Semaglutide cut body mass index by 16.1 per cent in children aged 12 to 17.
  • Tirzepatide cut body mass index by 18.5 per cent in adolescents aged 12 to under 18.
  • Children should receive these medicines only under a specialist doctor’s supervision.
Stat card: semaglutide cut body mass index by 16.1 per cent in the STEP TEENS study and 13.5 per cent in STEP Young; tirzepatide cut it by 18.5 per cent in SURMOUNT Adolescents after 72 weeks of treatment.

TOBA TEK SINGH: Childhood obesity is not just extra weight but a major risk to a child’s future health.

Doctors at the Metabo-Diabetes Nexus Symposium in Toba Tek Singh said timely weight control in childhood reduced the risk of insulin resistance and type 2 diabetes.

The symposium was held at Dullam Palace on Jhang Road on Friday, as part of World Diabetes Day events.

Timely weight control also improves blood pressure and bad cholesterol, reduces fat building up in the liver and eases pressure on breathing, sleep, bones and joints.

It builds children’s confidence and reduces feelings of inferiority.

The aim of weight loss in children is not just slimming but a healthy future protected from disease.

Controlling obesity in childhood may also help children avoid obesity, diabetes and heart disease as adults.

The symposium compared two medicines for children and adolescents: semaglutide and tirzepatide.

In the STEP TEENS study, children aged 12 to 17 lost weight, with body mass index falling 16.1 per cent.

In the STEP Young study, children aged six to under 12 saw a 13.5 per cent fall in body mass index.

In the SURMOUNT Adolescents study, adolescents aged 12 to under 18 saw an 18.5 per cent fall on tirzepatide.

“Children should receive these medicines only under a specialist doctor’s supervision.”

These results came after 72 weeks of treatment.

The medicines also help lower blood sugar, improve the body’s response to insulin and cut bad cholesterol and blood fats.

They may also reduce fat stored in the liver and return blood sugar to normal in children with prediabetes.

Blood pressure and heart disease risk factors may also improve.

Semaglutide has stronger research evidence in children, while tirzepatide showed more weight loss in its study.

A direct comparison is needed to say which medicine is better.

Children should receive these medicines only under a specialist doctor’s supervision.

اردو میں پڑھیں

Author Profile

Staff Report
Staff Report
The Grand Lines covers news that impacts lives, uncovers truths, and keeps you fully informed.
Emotion Map:

Most Read

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
↑